Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0189
COMMENTARY
|
KRAS mutation testing: Why is it now not recommended for colorectal cancer EGFR inhibitors treatment decision? |
Prof. Dr. Albrecht Encke, MD, PhD.
|
Affiliation: Prof. Dr. Albrecht Encke, Direktor der Chirurgische Universitätsklinik Frankfurt/Main, Theodor Stern Kai 7, 60590 Frankfurt/Main, Germany.
E-mail : A.Encke@em.uni-frankfurt.de |
Since there is no abstract available we provide the first paragraph
Mutation testing for identifying mutations in KRAS gene has become a standard for patients with advanced colorectal cancer for deciding on cetuximab. However, evidence is insufficient to support this approach. Two phase 3 trials accurately designed in the early and advanced colorectal cancer setting change this strategy. Why such a mutation testing cannot provide clinical utility and how can be explained the up and down of KRAS mutational status as predictive biomarker?
(Citation: Gastric & Breast Cancer 2011; 10(4) 220-222)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
